Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients

Abstract

We have compared the platelet number and the serum concentration of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6) in 80 blood samples of 50 patients with advanced cancer. We have also measured the mitogenic effect of patient sera on endothelial cells in vitro in order to estimate the biological activity of serum VEGF. Serum VEGF concentration correlated with platelet number (r = 0.61; P < 10(-4)). Serum IL-6 levels correlated with platelet count (r = 0.36; P < 10(-3)), with serum VEGF levels (r = 0.55; P < 10(-4)) and with the calculated load of VEGF per platelet (r = 0.4; P = 3 x 10(-4)). Patients with thrombocytosis had a median VEGF serum concentration which was 3.2 times higher (P < 10(-4)) and a median IL-6 serum level which was 5.8 times higher (P = 0.03) than in other patients. Serum bFGF did not show an association with any of the other parameters. Patient sera with high VEGF and bFGF content stimulated endothelial cell proliferation significantly more than other sera (P = 4 x 10(-3)). These results support the role of platelets in the storage of biologically active VEGF. Platelets seem to prevent circulating VEGF from inducing the development of new blood vessels except at sites where coagulation takes place. IL-6, besides its thrombopoietic effect, also seems to affect the amount of VEGF stored in the platelets. This is in accordance with the indirect angiogenic action of IL-6 reported previously. The interaction of IL-6 with the angiogenic pathways in cancer might explain the stimulation of tumour growth occasionally observed during IL-6 administration. It also conforms to the worse outcome associated with high IL-6 levels and with thrombocytosis in several tumour types and benign angiogenic diseases.

References 44

1. 1.
   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology · 1998

   No notice
2. 2.

   Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52(12):3317-3322.

   Not in our library

3. 3.

   Bousvaros A., Zurakowski D., Fishman S. J., Keough K., Law T., Sun C., Leichtner A. M. Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing. Dig Dis Sci. 1997;42(2):378-386.

   Not in our library10.1023/a:1018882322566

4. 4.

   Brekken R. A., Huang X., King S. W., Thorpe P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998;58(9):1952-1959.

   Not in our library

5. 5.

   Bross D. A., Leichtner A. M., Zurakowski D., Law T., Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1996;23(2):164-171.

   Not in our library10.1097/00005176-199608000-00012

6. 6.

   Clarke D., Johnson P. W., Banks R. E., Storr M., Kinsey S. E., Johnson R., Morgan G., Gordon M. Y., Illingworth J. M., Perren T. J. Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. Cytokine. 1996;8(9):717-723.

   Not in our library10.1006/cyto.1996.0095

7. 7.

   Cohen T., Nahari D., Cerem L. W., Neufeld G., Levi B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736-741.

   Not in our library10.1074/jbc.271.2.736

8. 8.

   Degeorges A., Tatoud R., Fauvel-Lafeve F., Podgorniak M. P., Millot G., de Cremoux P., Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer. 1996;68(2):207-214.

   Not in our library10.1002/(sici)1097-0215(19961009)68:2<207::aid-ijc12>3.0.co;2-7

9. 9.

   Dirix L. Y., Vermeulen P. B., Hubens G., Benoy I., Martin M., De Pooter C., Van Oosterom A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996;7(8):843-848.

   Not in our library10.1093/oxfordjournals.annonc.a010764

10. 10.
    Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients · 1997

    No notice
11. 11.

    Dosquet C., Coudert M. C., Lepage E., Cabane J., Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res. 1997;3(12 Pt 1):2451-2458.

    Not in our library

12. 12.

    Duensing S., Grosse J., Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res. 1995;15(5B):2331-2333.

    Not in our library

13. 13.

    Dvorak H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650-1659.

    Not in our library10.1056/nejm198612253152606

14. 14.

    Ferriere J. P., Bernard D., Legros M., Chassagne J., Chollet P., Gaillard G., Plagne R. beta-Thromboglobulin in patients with breast cancer. Am J Hematol. 1985;19(1):47-53.

    Not in our library10.1002/ajh.2830190107

15. 15.

    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.

    Not in our library10.1093/jnci/82.1.4

16. 16.

    Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer. 1996;32A(14):2379-2385.

    Not in our library10.1016/s0959-8049(96)00424-8

17. 17.

    Handagama P. J., Shuman M. A., Bainton D. F. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest. 1989;84(1):73-82.

    Not in our library10.1172/jci114173

18. 18.

    Harrison P., Wilbourn B., Debili N., Vainchenker W., Breton-Gorius J., Lawrie A. S., Masse J. M., Savidge G. F., Cramer E. M. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest. 1989;84(4):1320-1324.

    Not in our library10.1172/jci114300

19. 19.

    Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Hirano T., Kishimoto T., Takatsuki F., Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74(4):1241-1244.

    Not in our library

20. 20.

    Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52(11):2745-2756.

    Not in our library10.1172/jci107470

21. 21.

    Kaushansky K. Thrombopoietin: platelets on demand? Ann Intern Med. 1997;126(9):731-733.

    Not in our library10.7326/0003-4819-126-9-199705010-00009

22. 22.

    Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86(2):419-431.

    Not in our library

23. 23.

    Kumar H., Heer K., Lee P. W., Duthie G. S., MacDonald A. W., Greenman J., Kerin M. J., Monson J. R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998;4(5):1279-1285.

    Not in our library

24. 24.

    Lake A. M., Stauffer J. Q., Stuart M. J. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis. 1978;23(10):897-902.

    Not in our library10.1007/bf01072463

25. 25.

    Liotta L. A., Kleinerman J., Saidel G. M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34(5):997-1004.

    Not in our library

26. 26.

    Mateo R. B., Reichner J. S., Albina J. E. Interleukin-6 activity in wounds. Am J Physiol. 1994;266(6 Pt 2):R1840-R1844.

    Not in our library10.1152/ajpregu.1994.266.6.r1840

27. 27.

    Milroy R., Douglas J. T., Campbell J., Carter R., Lowe G. D., Banham S. W. Abnormal haemostasis in small cell lung cancer. Thorax. 1988;43(12):978-981.

    Not in our library10.1136/thx.43.12.978

28. 28.

    Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A. 1990;87(8):3092-3096.

    Not in our library10.1073/pnas.87.8.3092

29. 29.

    Möhle R., Green D., Moore M. A., Nachman R. L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663-668.

    Not in our library10.1073/pnas.94.2.663

30. 30.

    Nakano T., Chahinian A. P., Shinjo M., Tonomura A., Miyake M., Togawa N., Ninomiya K., Higashino K. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer. 1998;77(6):907-912.

    Not in our library10.1038/bjc.1998.150

31. 31.

    Pedersen L. M., Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826-1830.

    Not in our library10.1183/09031936.96.09091826

32. 32.

    Rak J. W., Hegmann E. J., Lu C., Kerbel R. S. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol. 1994;159(2):245-255.

    Not in our library10.1002/jcp.1041590208

33. 33.

    Rak J., Filmus J., Kerbel R. S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer. 1996;32A(14):2438-2450.

    Not in our library10.1016/s0959-8049(96)00396-6

34. 34.

    Ravoet C., DeGrève J., Vandewoude K., Kerger J., Sculier J. P., Lacor P., Stryckmans P., Piccart M. Tumour stimulating effects of recombinant human interleukin-6. Lancet. 1994;344(8936):1576-1577.

    Not in our library10.1016/s0140-6736(94)90387-5

35. 35.

    Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79(2):144-146.

    Not in our library10.1002/(sici)1097-0215(19980417)79:2<144::aid-ijc8>3.0.co;2-t

36. 36.

    Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90(8):3167-3172.

    Not in our library

37. 37.

    Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3(11):1222-1227.

    Not in our library10.1038/nm1197-1222

38. 38.

    Verheul H. M., Hoekman K., Luykx-de Bakker S., Eekman C. A., Folman C. C., Broxterman H. J., Pinedo H. M. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997;3(12 Pt 1):2187-2190.

    Not in our library

39. 39.

    Vermeulen P. B., Dirix L. Y., Martin M., Lemmens J., Van Oosterom A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J Natl Cancer Inst. 1997;89(17):1316-1317.

    Not in our library10.1093/jnci/89.17.1316

40. 40.

    Vermeulen P. B., Gasparini G., Fox S. B., Toi M., Martin L., McCulloch P., Pezzella F., Viale G., Weidner N., Harris A. L. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;32A(14):2474-2484.

    Not in our library10.1016/s0959-8049(96)00379-6

Cited by papers we hold 4

• Platelets and cancer angiogenesis nexus · 2017
  No notice
• Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer · 2007
  No notice
• Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients · 2003
  No notice
• Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer · 2002
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.